BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asselah T, Zeuzem S, Reau N, Hwang P, Long J, Talwani R, Robertson MN, Haber BA. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin 2020;36:1325-32. [PMID: 32459122 DOI: 10.1080/03007995.2020.1775075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Behloul N, Baha S, Guo Y, Yang Z, Shi R, Meng J. In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain. Eur J Pharmacol 2021;890:173701. [PMID: 33130279 DOI: 10.1016/j.ejphar.2020.173701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Hung HY, Chen CY, Liao YH. A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection. Front Pharmacol 2021;12:640317. [PMID: 34566631 DOI: 10.3389/fphar.2021.640317] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]